论文部分内容阅读
纳多洛尔(Nadolol)是一种长效、无内原性拟交感活性、无膜稳定作用、非选择性β受体阻滞剂。该药β受体阻滞作用较强,对心功能影响较小,同时具有增加肾血浆流量、半衰期长、中枢副作用小等显著优点。70年代后期,纳多洛尔开始用于临床治疗高血压、心绞痛、心律失常,甲状腺毒血症、偏头痛、肝硬变、巴金森氏综合征等。但用24h动态心电详细观察其对抗心律失常的治疗效果,文献报道甚少。现将我们用纳多洛尔治疗心律失常115例次的动态心电观察疗效结果报道如下。
Nadolol is a long-acting, non-endogenous sympathomimetic, membrane-free stabilizing, non-selective beta-blocker. The drug β receptor block stronger, less impact on cardiac function, while increasing renal plasma flow, long half-life, the central side effects of small significant advantages. In the late 1970s, nadolol began to be used in the clinical treatment of hypertension, angina, arrhythmia, thyrotoxicosis, migraine, cirrhosis, Parkinson’s syndrome and so on. However, 24h dynamic ECG detailed observation of its anti-arrhythmic effect, the literature reported little. Now we use nadolol treatment of arrhythmia 115 cases of dynamic ECG findings reported below.